Publications by authors named "C D Tuxen"
Article Synopsis
- * A study utilizing Danish registries analyzed 4,748 patients with infective endocarditis before and after the POET trial publication, examining changes in hospital length of stay (LOS) and outcomes like mortality and relapse of bacteremia.
- * Results showed a significant decrease in median LOS by 8 days post-POET publication, with no significant change in mortality rates but a notable reduction in relapse of bacteremia from 3.5% to 1.6%.
Article Synopsis
- The study analyzed data from the Empire HF trial to understand what factors influence physical activity levels in heart failure patients with reduced ejection fraction (HFrEF).
- It found that older age and anemia were linked to lower levels of accelerometer-measured physical activity, indicating that these factors negatively impact patients' activity.
- Additionally, while there was a slight increase in physical activity with improvements in self-reported health status, the correlation was weak, suggesting more research is needed to fully understand how activity levels relate to overall health.
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have previously demonstrated cardioprotective properties in patients with type 2 diabetes, suggesting a preventive effect on heart failure (HF). The Empire Prevent trial program investigates the therapeutic potential for HF prevention by evaluating the cardiac, metabolic, and renal effects of the SGLT2 inhibitor empagliflozin in patients with increased risk of developing HF, but without diabetes or established HF.
Methods: The Empire Prevent trial program is an investigator-initiated, double-blind, randomized clinical trial program including elderly and obese patients (60-84 years, body mass index >28 kg/m) with at least one manifestation of hypertension, cardiovascular or chronic kidney disease, but no history of diabetes or HF.
Introduction: Pleural effusion is present in half of the patients hospitalised with acute heart failure. The condition is treated with diuretics and/or therapeutic thoracentesis for larger effusions. No evidence from randomised trials or guidelines supports thoracentesis to alleviate pleural effusion due to acute heart failure.
View Article and Find Full Text PDFBackground: Whether continued follow-up in specialized heart failure (HF) clinics after optimization of guideline-directed therapy improves long-term outcomes in patients with HF with reduced ejection fraction (HFrEF) is unknown.
Methods And Results: 921 medically optimized HFrEF patients enrolled in the NorthStar study were randomly assigned to follow up in a specialized HF clinic or primary care and followed for 10 years using Danish nationwide registries. The primary outcome was a composite of HF hospitalization or cardiovascular death.